EpCAM overexpression in thyroid carcinomas - A histopothological study of 121 cases

被引:29
作者
Ensinger, Christian
Kremser, Roswitha
Prommegger, Rupert
Spizzo, Gilbert
Schmid, Kurt W.
机构
[1] Med Univ Innsbruck, Inst Pathol, A-6020 Innsbruck, Austria
[2] Med Univ Innsbruck, Inst Surg, A-6020 Innsbruck, Austria
[3] Med Univ Innsbruck, Inst Internal Med, A-6020 Innsbruck, Austria
[4] Univ Essen Gesamthsch, Inst Pathol, Essen, Germany
基金
芬兰科学院;
关键词
thyroid; carcinoma; EpCAM; immunohistochemistry; immunotherapy;
D O I
10.1097/01.cji.0000211303.52503.da
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial cell adhesion molecule (EpCAM) is expressed by a broad variety of carcinoma cells. It is recognized by the monoclonal antibody 17-1A, which has already been applied for immunotherapy of several carcinoma types in preclinical and small clinical studies. In the present study the immunohistochemical properties of 17-1A were evaluated in 121 cases of thyroid carcinomas of follicular cell origin, comprising of 75 differentiated (DTC; 35 papillary and 40 follicular carcinomas), 24 poorly differentiated (PDTC) and 22 anaplastic thyroid carcinomas. Overexpression of EpCAM, as recently defined. was found with a distinct membranous staining pattern in 81.3% of DTCs and in 66.6% of PDTCs. In contrast, all anaplastic thyroid carcinomas (0%) completely lacked EpCAM expression. Normal thyroid tissue presented with weak and heterogeneous EpCAM staining. This study demonstrates EpCAM overexpression as a common finding in DTCs and PDTCs. and thus these tumors as possible novel targets for EpCAM-directed immunotherapy. Our findings suggest that patients with recurrent or advanced tumor disease and metastatic spread could benefit from this modern therapeutic regime, especially after insufficient radioiodine therapy.
引用
收藏
页码:569 / 573
页数:5
相关论文
共 43 条
[1]  
[Anonymous], 2004, World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Endocrine Organs
[2]  
[Anonymous], 1992, ATLAS TUMOR PATHOL
[3]   EpCAM - A new therapeutic target for an old cancer antigen [J].
Armstrong, A ;
Eck, SL .
CANCER BIOLOGY & THERAPY, 2003, 2 (04) :320-325
[4]  
ASHFAQ R, 1994, CANCER, V73, P416, DOI 10.1002/1097-0142(19940115)73:2<416::AID-CNCR2820730229>3.0.CO
[5]  
2-O
[6]   The biology of the 17-1A antigen (Ep-CAM) [J].
Balzar, M ;
Winter, MJ ;
de Boer, CJ ;
Litvinov, SV .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (10) :699-712
[7]   ANAPLASTIC THYROID-CARCINOMA - A STUDY OF 70 CASES [J].
CARCANGIU, ML ;
STEEPER, T ;
ZAMPI, G ;
ROSAI, J .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1985, 83 (02) :135-158
[8]   POORLY DIFFERENTIATED (INSULAR) THYROID-CARCINOMA - A REINTERPRETATION OF LANGHANS WUCHERNDE STRUMA [J].
CARCANGIU, ML ;
ZAMPI, G ;
ROSAI, J .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1984, 8 (09) :655-668
[9]  
de Boer CJ, 1999, J PATHOL, V188, P201, DOI 10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO
[10]  
2-8